Press Releases

BRISBANE, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it will

BRISBANE, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that the Company's

Record Quarterly Revenue Reported

BRISBANE, Calif. , Aug. 14, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it will

BRISBANE, Calif. and PITTSBURGH , July 31, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA) a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients and Allegheny

Graft-Derived cfDNA in Bloodstream Correlates to Acute Cellular Rejection in Kidney as Well as in Heart Transplant Recipients

CareDx Announces Pricing of its IPO and Completion of its First Day of Trading Brisbane, CA July 17, 2014 CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts.